-
Fear on the Rise 06-16-2011
Thursday, June 16, 2011 - 6:56pm | 975Cusick's Corner Support held into the close and the After Hours finished in the green. Quad Witching is tomorrow where the options and futures all expire and the European options actually settle in the morning so there could be some maneuvering early based on the settlement. There is a lot of work...
-
Aastrom Files At-the-Market Offering and New Shelf Registration Statement
Thursday, June 16, 2011 - 4:39pm | 219Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that it has filed a prospectus supplement to sell shares of its common stock, no par value per share, at an aggregate offering amount of approximately $20 million through an "at-the-market" offering. If utilized, the shares would be offered...
-
Calls Purchased on Nabi Biopharmaceuticals
Thursday, June 16, 2011 - 12:44pm | 143Shares of Nabi Biopharmaceuticals (NASDAQ: NABI) are higher on the session by 2.52%, currently trading at $4.89. The stock has been moving largely lower over the past two months and is currently trading below the 200-day moving average. Options traders are buying calls on the name today. A short...
-
Celgene Announces Phase I/II Data Evaluating Clinical Benefit of REVLIMID in Combination with Standard R-CHOP Chemotherapy for Patients with Untreated Diffuse Large B-Cell Lymphoma
Thursday, June 16, 2011 - 12:16pm | 103Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two studies evaluating the use of REVLIMID with standard R-CHOP* chemotherapy in patients with untreated diffuse large B cell or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant...
-
Celgene Announces Phase II Study Evaluates Clinical Benefit of Combining REVLIMID with rituximab to Enhance Anti-Cancer Activity in Mantle Cell Lymphoma
Thursday, June 16, 2011 - 11:48am | 118Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from a Phase I/II study evaluating the combination of REVLIMID plus rituximab in relapsed/refractory mantle cell lymphoma, conducted by investigators at the MD Anderson Cancer Center in Houston, TX, were presented at the 11th...
-
Rosetta Genomics Announces Data Demonstrating the Ability of miRview mets(2) to Identify Tissue of Origin in Cancer of Unknown Primary Presented at ASCO 2011
Thursday, June 16, 2011 - 10:08am | 83Rosetta Genomics (NASDAQ: ROSG) announces that data presented at the American Society of Clinical Oncology 2011 showed the Company's miRview® mets(2) test accurately identified the tissue of origin in Cancer of Unknown Primary patients in a post-marketing validation study. Findings from a study...
-
Morning Market Movers
Thursday, June 16, 2011 - 9:45am | 174Parkvale Financial Corporation (NASDAQ: PVSA) shares surged 79.55% to $19.75 at 9:45 am. F.N.B. Corporation (NYSE: FNB) announced its plans to acquire Parkvale Financial for $22.48 per share, or $130 million. NeurogesX Inc (NASDAQ: NGSX) jumped 47.37% to $3.92. NGSX reported the completion of...
-
Cubist Pharmaceuticals Announces Positive Results From Drug Trials
Thursday, June 16, 2011 - 9:13am | 107Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced this morning that it had positive results from two Phase 2 trials, CXA-201 and CDAD Program. The company announced that CXA-201 is being used for intra-abdominal infections . “Positive results from these two Phase 2 clinical trials are...
-
Sterne Agee Reports Demand Weakness From Diodes Consumers
Thursday, June 16, 2011 - 9:07am | 101According Sterne Agee, Diodes (NASDAQ: CBLI) says it is seeing some demand weakness in the Analog Channel starting in May and the weakness from OEMs-Distributors has continued to date in June. Sterne Agee said that it believes the company feels this is just a minor correction in Semis and does not...
-
Wedbush Reiterates Outperform Rating On Cleveland BioLabs
Thursday, June 16, 2011 - 9:04am | 79According Wedbush, Cleveland BioLabs (NASDAQ: CBLI) Outperform rating is reiterated. Wedbush said that it remains bullish on the likelihood for CBLI to obtain a $50M BARDA award to continue the development of CBLB502. “We arrive at $10/share price target by adding net profits of CBLB502 from 2011...
-
J.P. Morgan Reiterates Overweight Rating On Dendreon
Thursday, June 16, 2011 - 8:54am | 67According J.P. Morgan, Dendreon (NASDAQ: DNDN) Overweight rating is reiterated. J.P. Morgan said that it reiterates its OW rating on DNDN ahead of important near-term developments. “For the second time this year, the company is approaching a clustering of events that could have significant...
-
Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL
Thursday, June 16, 2011 - 8:52am | 166Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee will review the company's Biologics License Applications for brentuximab vedotin on July 14, 2011. ODAC plans to review the BLA for the treatment of relapsed or...
-
LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark
Thursday, June 16, 2011 - 8:31am | 181Laboratory Corporation of America® Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on July 15, 2011, LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ: ORCH). On May 17...
-
NeurogesX Completes Phase 2 Enrollment of NGX-1998 Topical Liquid Capsaicin Formulation Trial
Thursday, June 16, 2011 - 8:01am | 71NeurogesX, Inc. (Nasdaq: NGSX) today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia. NGX-1998 is being developed to provide safety, efficacy and...
-
A Peek Into The Market Before The Trading Starts
Thursday, June 16, 2011 - 7:25am | 410Pre-open movers US stock futures are mixed this morning, as investors are awaiting several economic reports. Futures on the Dow Jones Industrial Average dipped 6 points to 11,825.00 and futures on the S&P 500 stock index rose 0.40 point to 1,260.30. Nasdaq 100 futures dropped 0.75 point to 2,...